Registry for prostate cancer ablation data
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
University of Chicago · NCT06705803
This study is creating a database to collect information from men with prostate cancer who are having ablation treatments to see how well these procedures work and what side effects they may cause.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 22 Years and up |
| Sex | Male |
| Sponsor | University of Chicago (other) |
| Locations | 2 sites (Hyde Park, Illinois and 1 other locations) |
| Trial ID | NCT06705803 on ClinicalTrials.gov |
What this trial studies
This study aims to create a comprehensive database and registry for patients with prostate cancer who are undergoing prostate ablation procedures. It focuses on collecting data regarding the efficacy and side effects of various ablation techniques, including cryotherapy and high-intensity focused ultrasound. By gathering this information, the study seeks to evaluate the long-term outcomes of prostate ablation as a treatment option that balances active surveillance and radical therapy. The registry will include patients who are either scheduled for or have already undergone ablation as part of their clinical care.
Who should consider this trial
Good fit: Ideal candidates for this study are men aged 22 and older with a histologic diagnosis of prostate cancer who are scheduled to undergo or have undergone prostate ablation.
Not a fit: Patients under 21 years of age or those not undergoing prostate ablation will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term effectiveness and safety of prostate ablation, potentially improving treatment options for prostate cancer patients.
How similar studies have performed: While there is ongoing interest in prostate ablation techniques, this registry approach is relatively novel and aims to fill gaps in existing data regarding long-term outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male sex * ≥22 years of age * Histologic diagnosis of prostate cancer * Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials * Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins Exclusion Criteria: * Under 21 Years of age.
Where this trial is running
Hyde Park, Illinois and 1 other locations
- The University of Chicago — Hyde Park, Illinois, United States (RECRUITING)
- The University of Cinncinatti — Cincinnati, Ohio, United States (RECRUITING)
Study contacts
- Principal investigator: Abhinav Sidana, MD — University of Chicago
- Study coordinator: Abhinav Sidana, MD
- Email: abhinav.sidana@bsd.uchicago.edu
- Phone: 773-834-5087
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer